Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US03843E1047
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00L9HP0Z0
AQST
Aquestive Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Drug Manufacturers - Specialty & Generic · THEMEFOLIO: $HLTH
NAME
Aquestive Therapeutics Inc
ISIN
US03843E1047
TICKER
AQST
MIC
XNAS
REUTERS
AQST.OQ
BLOOMBERG
AQST US
Do., 19.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, March 19, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, March 18, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 20...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Aquestive Therapeutics
US03843E1047

On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who purchased AQST securities between June 16, 2025 and January 8, 2026 lost over 37% of their investment...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 15.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Sa., 14.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 12, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, March 12, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 11.03.2026       Aquestive Therapeutics
US03843E1047

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026. Aquestive describes itself as a “pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Aquestive Therapeutics
US03843E1047

Levi & Korsinsky, LLP alerts investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) that Daniel Barber, the Company's Chief Executive Officer, President, and Director, is named as an individual defendant in a pending securities class action. Class Period: June 16, 2025 through January 8, 2026. Find out if you qualify to recover losses or con...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 10.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced an inducement grant for Matthew Greenhawt, MD, MBA, MSc,...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 08.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       Aquestive Therapeutics
US03843E1047

SAN DIEGO, March 6, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring impr...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260306007771/en/ Faruqi & Faruqi is a leading natio...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       Aquestive Therapeutics
US03843E1047

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through innova...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 04.03.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today reported financial results for the fourth quarter and full year end...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 28.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended D...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 21.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 20.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple poster presentations highlighting results fr...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 07.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 06.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Aquestive Therapeutics to Contact Him Directly to Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Aquestive Therapeutics
US03843E1047

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or “the Company”) (NASDAQ: AQST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws.What Happened?On January 9, 2026, Aquestive announced it received a...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 31.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 27.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 26.01.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws.What Happened?On January 9, 2026, Aquestive announced it received a...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 22.01.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink